Journal article

Clinical Features and Outcome in HIV-Associated Multicentric Castleman's Disease

Mark Bower, Tom Newsom-Davis, Kikkeri Naresh, Shairoz Merchant, Belinda Lee, Brian Gazzard, Justin Stebbing, Mark Nelson

JOURNAL OF CLINICAL ONCOLOGY | AMER SOC CLINICAL ONCOLOGY | Published : 2011

Abstract

PURPOSE: To describe clinical features, treatment outcomes and relapse rates in HIV-associated multicentric Castleman's disease (MCD) in a sizeable mature cohort. METHODS: From a prospective database, we identified 61 HIV-seropositive patients with histologically confirmed MCD (median follow-up, 4.2 years). Since 2003, 49 patients with newly diagnosed MCD have been treated with rituximab with (n = 14) or without (n = 35) etoposide. RESULTS: At MCD diagnosis, 55 (90%) of 61 patients met proposed clinical criteria defining an attack. Four patients (7%) had histologic evidence of coexisting lymphoma, and one developed lymphoma 2 years after treatment. The incidence of lymphoma is 28 per 1,000 p..

View full abstract

University of Melbourne Researchers